ArriVent BioPharma, Inc.: Form 8-K/A, filed Jul 9, 2024
Filed with the SEC on Jul 9, 2024 and accepted by EDGAR at Jul 9, 2024, 17:03 ET.
Items reported
- Item 5.02 Departure or appointment of officers or directors
- Item 9.01 Financial statements and exhibits
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Source: SEC EDGAR, the filing index for accession 0001104659-24-078585. Last ingested by Listed: Nov 5, 2026, 13:51 ET. Listed shows no prices and gives no investment advice.